Karen J. Wilson, a director at Serina Therapeutics, Inc. (NASDAQ:SER), recently acquired $17,749 worth of the company’s common stock. The transactions occurred over two days, according to a Form 4 filing with the Securities and Exchange Commission dated June 15, 2026, for activity reported on June 11 and June 12, 2026.
On June 11, Ms. Wilson purchased 5,100 shares of common stock. The price paid was a weighted average of $1.745 per share, with individual transaction prices ranging from $1.745 to $1.75 per share.
The following day, June 12, she acquired an additional 5,000 shares of common stock. These shares were purchased at a weighted average price of $1.77 per share, with individual transaction prices ranging from $1.76 to $1.77 share.
The insider purchase comes as Serina Therapeutics stock trades at $1.93, down 69% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, with the company holding a market cap of $27.26 million. InvestingPro offers 11 additional exclusive tips for SER investors.
Following these acquisitions, Ms. Wilson directly holds 10,100 shares of Serina Therapeutics common stock.
In other recent news, Serina Therapeutics, Inc. announced key changes in its executive team and corporate governance structure. The company appointed Srini Tenjarla, Ph.D., as the new Chief Technology Officer of its wholly owned subsidiary, Serina Therapeutics (AL), Inc. Dr. Tenjarla, who previously held the position of Senior Vice President of CMC and Formulation since July 2024, will now receive an annual base salary of $425,000, effective retroactively from March 15, 2026. These developments were disclosed in a press release following the company’s latest SEC filing.